The Microbiome Business & Science Briefing
MicrobimeTimes
Reporting on The Latest Microbiome Business & Scientific Developments
TRENDING
MaaT Pharma Provides Update on MaaT013 (Xervyteg®) Potential Development Plan Following CHMP Negative Opinion After Re-examination• Evvy Raises $40M Series B to Scale AI-Powered Precision Diagnostics & Care Platform for Women’s Health• Armata Pharmaceuticals Receives U.S. FDA Breakthrough Therapy Designation for AP-SA02• GutAlive®: Microbiota Collection and Transport in Anaerobic Conditions• From Discovery to Disease Prevention: How the Biose–Siolta Partnership is Advancing a New Generation of Live Biotherapeutics• A pioneering gut bacterium passes Europe’s food-safety review under the EU Novel Food Regulation•

Microbiome Times

Axial Therapeutics Raises $37.25 Million in Series C Financing
Finance

Axial Therapeutics Raises $37.25 Million in Series C Financing

OCT 13, 2021
Framing the Narrative on CMC Development for Microbiome Therapeutics
Finance

Framing the Narrative on CMC Development for Microbiome Therapeutics

OCT 12, 2021
Intralytix Receives FDA Regulatory Clearance for Phage-Based Campylobacter Technology
Pharma & Human Health

Intralytix Receives FDA Regulatory Clearance for Phage-Based Campylobacter Technology

OCT 11, 2021
Vedanta Announces Positive Topline Phase 2 Data for VE303 in High-Risk C. difficile Infection and Exercise of $23.8 Million Option by BARDA
Clinical & Manufacturing

Vedanta Announces Positive Topline Phase 2 Data for VE303 in High-Risk C. difficile Infection and Exercise of $23.8 Million Option by BARDA

OCT 5, 2021
Changing requirements for anaerobic culture equipment in microbiome research and product development
Pharma & Human Health

Changing requirements for anaerobic culture equipment in microbiome research and product development

OCT 5, 2021
L’Oréal Singapore and NTU Singapore set up joint lab hosted by SCELSE for deeper exploration of skin and scalp microbiomes
Pharma & Human Health

L’Oréal Singapore and NTU Singapore set up joint lab hosted by SCELSE for deeper exploration of skin and scalp microbiomes

OCT 4, 2021
Ferring Presents Complete Data across Five RBX2660 Trials Demonstrating Consistent and Durable Efficacy in Recurrent C. Difficile Infection
Editor's Choice

Ferring Presents Complete Data across Five RBX2660 Trials Demonstrating Consistent and Durable Efficacy in Recurrent C. Difficile Infection

SEP 30, 2021
Clinical Trial Expert Discussion: Study Design for Microbiome Therapies
Clinical & Manufacturing

Clinical Trial Expert Discussion: Study Design for Microbiome Therapies

SEP 28, 2021
Evelo Biosciences Announces Positive Phase 2 Clinical Data with EDP1815 in Psoriasis
Clinical & Manufacturing

Evelo Biosciences Announces Positive Phase 2 Clinical Data with EDP1815 in Psoriasis

SEP 27, 2021
Synlogic Announces Positive Phase 2 Data Demonstrating Reduction in Plasma Phenylalanine Levels in Patients with Phenylketonuria
Clinical & Manufacturing

Synlogic Announces Positive Phase 2 Data Demonstrating Reduction in Plasma Phenylalanine Levels in Patients with Phenylketonuria

SEP 20, 2021
MD Anderson and SNIPR BIOME collaborate to advance next-generation CRISPR microbiome therapeutics
Finance

MD Anderson and SNIPR BIOME collaborate to advance next-generation CRISPR microbiome therapeutics

SEP 15, 2021